It’s Freezing and I’m Stuck on My Scooter
It happened on the coldest day of the season. It was 16 degrees F with wind chill. I was outside,…
Articles by Ed Tobias
MS News that Caught My Eye Last Week: Mayzent in EU for SPMS; Depression, Fatigue, and Quality of Life; Acthar Gel; Soothie Cushion
CHMP Favors Mayzent as Oral Treatment Specifically for Active SPMS Patients in EU Mayzent (siponimod) is one of the…
Is It Good that Google Is Crunching Our Healthcare Data?
Google has quietly teamed up with Ascension, one of the largest healthcare organizations in the United States, to process…
MS News that Caught My Eye Last Week: EU Lemtrada Safety Guidance, Targeted Treatment Project, SPMS Patients Unaware of Diagnosis
EMA Safety Group Advises Lemtrada Be Limited to ‘Highly Active’ RRMS Patients at Hospitals with ICUs I’m highlighting this…
Top MS Worries Highlight the Need for a Comprehensive Care Program
What worries you most about living with multiple sclerosis? I’m catching up with a small survey by Can Do…
MS News that Caught My Eye Last Week: Vumerity Approval, Low Antibody Levels in MS Patients, GA Depot Trial, Tecfidera Study
Vumerity Approved in US as Treatment for RRMS and Active SPMS By my count, Vumerity is the 18th…
My Lemtrada Journey: Observations at 18 Months After Round 2
It’s time for another update on how I’ve been doing with my Lemtrada (alemtuzumab) treatments. The bottom line is…
MS News that Caught My Eye Last Week: Cognitive Impairment, Genetic Variant Risk Factor, Protein Biomarkers, Gilenya Study
Higher Intellectual Ability, Early-life Physical Activity May Protect Against Cognitive Impairment in MS, Study Suggests The finding that physical…
Am I Too Old for Aggressive MS Treatment?
A question raised by neurologist Gavin Giovannoni on the Barts-MS blog lit up my radar recently. Dr. G asked…
MS News that Caught My Eye Last Week: Injectable DMTs, Ofatumumab ‘Success Story,’ MS and Night Shift Work, MS Biomarker Study
#ECTRIMS2019 – Are Injectables Inappropriate for Active Relapsing MS Treatment? Injectable disease-modifying therapies (DMTs) have been around for a…
Pushing to Put a Symbol for Invisible Disabilities on Driver’s Licenses
This is not the week to tell me how good I look … even if I look and feel good.
MS News that Caught My Eye Last Week: Mavenclad and Ocrevus Use Rising in EU, Ampyra Patent Appeal Denied, Exercise and MS Pilot Study
Mavenclad, Ocrevus Use Rising in EU as Injectables and Tysabri Decline, Spherix Reports I’m not surprised at reports that…
It’s Not All in Your Head
Several days ago, the headline “It’s All in Your Head” jumped out at me. The author of the Journal…
MS News that Caught My Eye Last Week: Rituximab vs. Ocrevus
In this week’s column, I’ve changed the format a little to focus on one subject: rituximab. This is an approved…
My Fortuitous Footwear Discovery: I Found the Right MS Shoes
The other night, I had an MS dream. In it, I was able to lift my left leg as well…
Taking Vitamin D for Your MS? Use It Wisely
Many people with multiple sclerosis (MS) use vitamin D supplements. I’ve been popping a 2,000 IU tablet of vitamin D3…
MS News that Caught My Eye Last Week: Ozanimod, Achtar Gel, Onset Age Progression Link, Glial Cells Could Differentiate MS Types
In this column, I take a look at more exciting research from the ECTRIMS2019 conference this month. #ECTRIMS2019 –…
Neuros Say that Flu Shots and Other Vaccines Are OK for Those with MS
This is the time of year when my wife and I start thinking about getting our flu shots. We’ve already…
MS News that Caught My Eye Last Week: Stem Cell Transplants, Remyelination Agent, Tecfidera Study, Plasma Exchange and Tysabri-linked PML
It’s been a big week for interesting stories, as the annual meeting of the European Committee for Treatment and Research…
Stem Cell Program That Treated Selma Blair Closes Its Doors
Richard Burt, MD, the chief of Northwestern Medicine’s immunotherapy for autoimmune diseases division, is taking a…
MS News that Caught My Eye Last Week: Cancer Medication Slows MS, Vitamin D and Myelin, Targeting ‘Helper’ T-cells, Vaccination Guidelines
Ofatumumab Better at Easing Relapse Rates and Slowing MS Progression Than Aubagio, Phase 3 Data Show Ofatumumab isn’t approved…
Social Cognition: Does It Impact MS Symptoms?
Feeling tired, depressed, or anxious? Maybe it has to do with your social cognition. Social cognition involves empathy and…
Another Study Shows That Costs of Disease-modifying Therapies Are Zooming
It probably comes as no surprise to you that the costs of some of the most popular MS medications have…
I Dreamed That I Was Walking
When asleep, many people dream they can fly. Some dream about being naked in public, failing an exam, or…
MS News that Caught My Eye Last Week: Rituximab Helps Reverse Boy’s MS, Top Secondary DMTs in Europe, Tricking Remyelination, Early MS Treatment Strategies
Rituximab Leads to ‘Dramatic’ Recovery in Boy with Aggressive RRMS, Case Study Reports I dislike using adjectives such as…
Are Your MS Disease-modifying Treatments Old School or New School?
Choosing which MS medication to use is one of the most difficult decisions for someone with MS and their neurologist.
MS News that Caught My Eye Last Week: Dark Rimmed Lesions, Sativex in the UK, NHS Care Toolkit for Neurological Diseases, Wahls Diet
Dark Rimmed Brain Lesions May Be Signal of Aggressive Disease, NIH Study Says Researchers in this study found that…
MS Progression’s Speed Tagged to ‘Smoldering’ Brain Inflammation
The presence of chronic active lesions in the brain may provide a clue as to how quickly multiple sclerosis (MS)…
Keeping a Positive Attitude with Advocacy: Why I Write ‘The MS Wire’
This month marks the third anniversary of my column, “The MS Wire.” After writing two columns a week for…
MS News that Caught My Eye Last Week: Solution for Lemtrada Complications, CBD Infusions, Vaccines and MS, Music and Exercise
Autoimmune Complications Associated with Lemtrada Solved Using Anti-CD20 Therapies, Case Studies Suggest One of the concerns about the disease-modifying…